Drug intelligence / Profile preview

compound 7j

Development stage: Preclinical
Modality: Small Molecules

Overview

Compound 7j is an experimental **small-molecule pyranone-carbamate derivative** reported in a preclinical medicinal chemistry series being explored for **Alzheimer's disease**. It was described as a **butyrylcholinesterase inhibitor**, with reported inhibitory activity against equine BuChE in the low-nanomolar range, and belongs to a set of compounds designed to modulate cholinesterase activity and neuroinflammation. Based on the provided evidence, it appears to be an **early research compound** from an academic discovery program rather than a named clinical development asset, with no identified brand name, manufacturer, or clearly disclosed corporate developer.

Other names: pyranone-carbamate derivative 7jbenzylpiperazine-substituted pyranone-carbamate derivative 7j

Targets

Butyrylcholinesterase

Beyond the preview

Go deeper on compound 7j.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 7j.

Explore the full profile